- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06055920
El estudio PEERLESS II
PEERLESS II: ECA de FlowTriever versus anticoagulación sola en la embolia pulmonar
This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Augsburg, Alemania
- University Hospital Augsburg
-
Bad Krozingen, Alemania
- Universitäts-Herzzentrum Bad Krozingen
-
Berlin, Alemania
- Charité Campus Virchow Clinic - Klinik fuer Radiologie
-
Berlin, Alemania
- Unfall Krankenhaus Berlin
-
Cologne, Alemania
- University Hospital Cologne
-
Dresden, Alemania
- HerzZentrum Dresden Universitaetsklinik
-
Düsseldorf, Alemania
- Universitaetsklinikum Dὒsseldorf
-
Essen, Alemania
- Universitaetsklinikum Essen
-
Essen, Alemania
- Elisabeth Hospital GmbH
-
Frankfurt, Alemania
- CCB Frankfurt
-
Hamburg, Alemania
- Universitaetsklinikum Hamburg Eppendorf
-
Heidelberg, Alemania
- University Hospital - Heidelberg
-
Kaiserslautern, Alemania
- Westpfalz Klinikum
-
Munich, Alemania
- Klinikum rechts der Isar (TUM)
-
Munich, Alemania
- Ludwig Maximilians-University
-
Regensburg, Alemania
- University Hospital Regensburg
-
Villingen-Schwenningen, Alemania
- Schwarzwald-Baar-Klinikum
-
-
-
-
-
Aalst, Bélgica
- Onze Lieve Vrouwziekenhuis
-
-
-
-
British Columbia
-
New Westminster, British Columbia, Canadá, V3L 3W7
- Royal Columbian Hospital
-
Surrey, British Columbia, Canadá, V3V 1Z2
- Surrey Memorial Hospital
-
Vancouver, British Columbia, Canadá, V5Z 1M9
- Vancouver General Hospital
-
-
-
-
-
Aarhus, Dinamarca, 8200
- Aarhus University Hospital
-
-
-
-
-
Madrid, España
- Hopital Clinico Universitario San Carlos
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35243
- Brookwood Medical Center
-
Birmingham, Alabama, Estados Unidos, 35205
- UAB Division of Cardiovascular Disease
-
-
California
-
Pasadena, California, Estados Unidos, 91105
- Huntington Memorial Hospital
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- University of Colorado, Denver
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06520
- Yale University
-
-
Florida
-
Largo, Florida, Estados Unidos, 33770
- HCA FL Largo Medical Center
-
Orlando, Florida, Estados Unidos, 32803
- AdventHealth Orlando
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Emory University
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern University
-
-
Michigan
-
Lansing, Michigan, Estados Unidos, 48910
- McLaren Greater Lansing
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64111
- Saint Luke's Hospital of Kansas City
-
Springfield, Missouri, Estados Unidos, 65804
- Mercy Hospital Springfield
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68105
- Nebraska Medical Center
-
-
New Jersey
-
Camden, New Jersey, Estados Unidos, 08103
- Virtua Health
-
-
New York
-
Buffalo, New York, Estados Unidos, 14203
- SUNY, The University of Buffalo/Gates Vascular
-
New York, New York, Estados Unidos, 10075
- Northwell Health
-
Rochester, New York, Estados Unidos, 14642
- University of Rochester Medical Center
-
Stony Brook, New York, Estados Unidos, 11794
- Stony Brook University Hospital
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- University of Cincinnati Medical Center
-
Cleveland, Ohio, Estados Unidos, 44195
- The Cleveland Clinic Foundation
-
Columbus, Ohio, Estados Unidos, 43210
- Ohio State University - Wexner Medical Center
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Estados Unidos, 18015
- St. Luke's University Hospital
-
Erie, Pennsylvania, Estados Unidos, 16507
- UPMC Hamot
-
Erie, Pennsylvania, Estados Unidos, 16505
- AHN Saint Vincent Hospital
-
Harrisburg, Pennsylvania, Estados Unidos, 17101
- UPMC Harrisburg
-
Philadelphia, Pennsylvania, Estados Unidos, 19144
- Thomas Jefferson University
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- The University of Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213
- UPMC Heart and Vascular Institute
-
Pittsburgh, Pennsylvania, Estados Unidos, 15212
- Allegheny Health Network Research Institute
-
York, Pennsylvania, Estados Unidos, 17403
- Wellspan York Hospital
-
-
Tennessee
-
Brentwood, Tennessee, Estados Unidos, 37027
- HCA Tristar
-
Knoxville, Tennessee, Estados Unidos, 37920
- UTMC Knoxville
-
Nashville, Tennessee, Estados Unidos, 37203
- Ascension Saint Thomas Hospital
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75235
- Parkland Hospital
-
Fort Worth, Texas, Estados Unidos, 76104
- Texas Health Harris Methodist Hospital
-
San Antonio, Texas, Estados Unidos, 78229
- Methodist Main Hospital
-
Temple, Texas, Estados Unidos, 76508
- Baylor Scott & White - Temple
-
-
Virginia
-
Falls Church, Virginia, Estados Unidos, 22042
- Inova Fairfax
-
-
West Virginia
-
Charleston, West Virginia, Estados Unidos, 25304
- Charleston Area Medical Center
-
Morgantown, West Virginia, Estados Unidos, 26506
- West Virginia University Ruby Memorial Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53215
- Aurora Saint Luke's Medical Center
-
-
-
-
-
Lille, Francia
- CHU Lille
-
Lyon, Francia
- Hôpital Louis Pradel
-
Marseille, Francia
- Hôpital Nord Marseille
-
Marseille, Francia
- AP-HM Hopital La Timone
-
-
-
-
-
Basel, Suiza
- Universitaetsspital Basel
-
Bern, Suiza
- Universitätsspital Bern
-
Lucerne, Suiza
- Luzerner Kantonsspital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Age at enrollment ≥ 18 years
-
Objective evidence of a proximal filling defect in at least one main or lobar pulmonary artery, as confirmed by CTPA, pulmonary angiography, or other imaging modality
-
RV dysfunction, as defined as one or more of the following: RV/LV ratio ≥ 0.9 or RV dilation or hypokinesis
-
At least two additional risk factors, identified by at least one measure in two separate categories noted below:
a. Hemodynamic: i. SBP 90-100mmHg ii. Resting heart rate > 100 bpm b. Biomarker: i. Elevated* cardiac troponin (troponin I or troponin T, conventional or high sensitivity) ii. Elevated* BNP or NT-proBNP iii. Elevated venous lactate ≥2 mmol/L * Elevated, meaning at or above the upper limit of normal, per local standards for the assay used c. Respiratory: i. O2 saturation < 90% on room air ii. Supplemental O2 requirement ≥ 4 L/min iii. Respiratory rate ≥ 20 breaths/min iv. mMRC score > 0
-
Symptom onset within 14 days of confirmed PE diagnosis
-
Willing and able to provide informed consent
Exclusion Criteria:
-
Unable to be anticoagulated with heparin, enoxaparin or other parenteral antithrombin
-
Presentation with hemodynamic instability* that meets the high-risk PE definition in the 2019 ESC Guidelines1, including ANY of the following
- Cardiac arrest OR
- Systolic BP < 90 mmHg or vasopressors required to achieve a BP ≥ 90 mmHg despite adequate filling status, AND end-organ hypoperfusion OR
- Systolic BP < 90 mmHg or systolic BP drop ≥ 40 mmHg, lasting longer than 15 min and not caused by new-onset arrhythmia, hypovolemia, or sepsis * Patients who are stable at time of screening or randomization (i.e., SBP ≥ 90 mmHg and adequate organ perfusion without catecholamine or vasopressor infusion) may be included despite initial presentation including temporary, low-dose catecholamines or vasopressors, or temporary fluid resuscitation.
-
Known sensitivity to radiographic contrast agents that, in the Investigator's opinion, cannot be adequately pre-treated
-
Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the patient is not appropriate for catheter-based intervention (e.g., inability to navigate to target location, clot limited to segmental/subsegmental distribution, predominately chronic clot)
-
End stage medical condition with life expectancy < 3 months, as determined by the Investigator
-
Current participation in another drug or device study that, in the investigator's opinion, would interfere with participation in this study
-
Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis, per 2019 ESC Guidelines1
-
If objective testing was performed*, estimated RV systolic pressure > 70 mmHg on standard of care echocardiography * If clinical suspicion of acute-on-chronic PE, chronic obstruction, or chronic thromboembolism, echocardiographic estimated RVSP must be confirmed ≤70 mmHg to meet eligibility. Pressure assessment not required if Investigator attests to absence of such clinical suspicion
-
Administration of advanced therapies (thrombolytic bolus, thrombolytic drip/infusion, catheter-directed thrombolytic therapy, mechanical thrombectomy, or ECMO) for the index PE event within 30 days prior to enrollment
-
Ventricular arrhythmias refractory to treatment at the time of enrollment
-
Known to have heparin-induced thrombocytopenia (HIT)
-
Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments). This includes a contraindication to use of FlowTriever System per local approved labeling
-
Subject is currently pregnant
-
Subject has previously completed or withdrawn from this study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: FlowTriever
Mechanical thrombectomy for pulmonary embolism using the FlowTriever System. |
Mechanical Thrombectomy for pulmonary embolism |
|
Comparador activo: Anticoagulation
Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. Anticoagulants are a group of medications that decrease your blood's ability to clot. |
Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. Anticoagulants are a group of medications that decrease your blood's ability to clot. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Composite clinical endpoint constructed as a win ratio, a hierarchy of the following, which are assessed post-randomization:
Periodo de tiempo: through discharge or 30 days, whichever is sooner / dyspnea at 48 hours
|
|
through discharge or 30 days, whichever is sooner / dyspnea at 48 hours
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Mortalidad por todas las causas y relacionada con la EP
Periodo de tiempo: A los 30 y 90 días
|
A los 30 y 90 días
|
|
|
Reingresos por todas las causas y relacionados con EP
Periodo de tiempo: A los 30 y 90 días
|
A los 30 y 90 días
|
|
|
6 minutos a pie
Periodo de tiempo: En la visita del mes
|
En la visita del mes
|
|
|
Relación VD/VI
Periodo de tiempo: En la visita de 48 horas
|
En la visita de 48 horas
|
|
|
Diagnóstico de deterioro post-PE (PPEI)
Periodo de tiempo: Durante la visita de 3 meses
|
Durante la visita de 3 meses
|
|
|
Composite clinical endpoint constructed as a win ratio hierarchy of the following three components, assessed post randomization:
Periodo de tiempo: up to 30 days
|
|
up to 30 days
|
|
Clinical deterioration
Periodo de tiempo: Through discharge or up to 30 days after randomization, whichever is sooner
|
defined by hemodynamic or respiratory worsening |
Through discharge or up to 30 days after randomization, whichever is sooner
|
|
Bailout therapy
Periodo de tiempo: Through discharge or up to 30 days after randomization, whichever is sooner
|
either after a deterioration or after documented failure to progress, |
Through discharge or up to 30 days after randomization, whichever is sooner
|
|
Major Bleeding, defined by the Bleeding Academic Research Consortium (BARC), level 3b, 3c, 5a, or 5b
Periodo de tiempo: At 30 and 90 days
|
3b: Overt bleeding plus hemoglobin drop of ≥ 5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade, bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid); bleeding requiring intravenous vasoactive agents 3c: Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal), subcategories confirmed by autopsy or imaging or lumbar puncture, intraocular bleed compromising vision. 5a: Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious 5b: Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation |
At 30 and 90 days
|
|
Dyspnea severity by mMRC score
Periodo de tiempo: At the 48-hour, 1-month, and 3-month visits
|
0, no breathlessness except on strenuous exercise;
|
At the 48-hour, 1-month, and 3-month visits
|
|
PE-related quality of life, by PEmb-QoL
Periodo de tiempo: At the 1- and 3-month visits
|
Pulmonary Embolism Quality of Life: (higher = better) |
At the 1- and 3-month visits
|
|
General health-related quality of life, by EQ-5D-5L
Periodo de tiempo: At the 1- and 3-month visits
|
Higher score = worse |
At the 1- and 3-month visits
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Jay Giri, MD, Penn Medicine
- Investigador principal: Bernhard Gebauer, MD, Charité University Hospital Berlin
- Investigador principal: Felix Mahfoud, MD, Universitaetsspital Basel
- Investigador principal: Frances Mae West, MD, Jefferson Health
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 23-001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .